Referencer - Behandlingsvejledning

1. Faught E. The Cost of the Second Seizure: Rethinking the Treatment Decision. Epilepsy Curr. 2019;19(2):88-90.
2. Ben-Menachem E. Medical management of refractory epilepsy--practical treatment with novel antiepileptic drugs. Epilepsia. 2014;55 Suppl 1:3-8.
3. Park KM, Kim SE, Lee BI. Antiepileptic Drug Therapy in Patients with Drug-Resistant Epilepsy. J Epilepsy Res. 2019;9(1):14-26.
4. Brigo F, Ausserer H, Tezzon F, Nardone R. When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy. Epilepsy Behav. 2013;27(3):439-42.
5. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409-31.
6. Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010;8(3):254-67.
7. Gastrup S, Stage TB, Fruekilde PB, Damkier P. Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. Br J Clin Pharmacol. 2016;81(4):735-41.
8. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-76.
9. Johannessen SI, Landmark CJ. Value of therapeutic drug monitoring in epilepsy. Expert Rev Neurother. 2008;8(6):929-39.
10. Perucca E. Extended-release formulations of antiepileptic drugs: rationale andcomparative value. Epilepsy Curr. 2009;9(6):153-7
11. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261(22):3273-7.
12. Holtkamp M, Theodore WH. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy? Epilepsia. 2018;59(7):1273-81.
13. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70(5):605-21.
14. Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. The Lancet Neurology. 2016;15(4):365-72.